<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02153411</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-RME-XXX-2014/1</org_study_id>
    <secondary_id>NIS-RME-XXX-2014/1</secondary_id>
    <nct_id>NCT02153411</nct_id>
  </id_info>
  <brief_title>Multicentric, Transversal, Descriptive, Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population</brief_title>
  <acronym>ESMAA</acronym>
  <official_title>Evaluation of aSthma Management in Middle EAst Adult Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Algeria: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Descriptive study on the management of asthma in asthmatic Middle East adult population :
      Algeria,Egypt, Irak,Iran, Jordan, Koweit, Lebanon, Qatar,Saudi,Tunisia, UAE
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentric, transversal, descriptive, epidemiological study, conducted in a random sample
      of general practitioner and medical specialist (Pulmonologist and/or allergologist) in the
      public and the private sector.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Asthma control</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daytime symptoms Limitation of activities Nocturnal symptoms / awakening Need for reliever /rescue treatment Lung function (PEF or FEV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>general and sociodemographic patient's characteristics</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>sex, age, BMI, educational level, occupation, comorbidities, smoking status, and social security coverage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify predictive factors of asthma control,</measure>
    <time_frame>UP to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>such as age, sex, BMI, smoking status, adherence to treatment, asthma history, comorbidity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asthma control level</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Asthma control test questionnaire : activities at work,breathless,asthma symptoms (wheezing, coughing, chest tightness, shortness of breath;use of rescue inhaler or taken a nebulizer treatment ,asthma assessment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8645</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>8645 asthmatic  patients</arm_group_label>
    <description>Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Asthmatic since at least one year before inclusion. Patient's informed consent obtained.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women, 18 years of age and older. Asthmatic since at least one year before
        inclusion. Patient's informed consent obtained.

        Exclusion Criteria:

          -  Patient concurrently participating to another study. Patient with concomitant
             pulmonary disease. Patient with psychiatric disorders. Patient consulting for an
             asthma attack
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karima KADI, Medical Director</last_name>
    <phone>00213 770 260 866</phone>
    <email>karima.kadi@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antoine Estephan, MEA Medical Director</last_name>
    <phone>+971 561148038</phone>
    <email>antoine.estephan@astrazeneca.com</email>
  </overall_contact_backup>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma control</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
